Life Matters
Fighting Antibiotic-resistant Bacteria via Biofilm Prevention
Company Overview
Snapshot
Founded in July 2016 by Amit Elbaz, Prof. Robert S. Marks, Karina Golberg, and Prof. Ariel Kushmaro, Life Matters operates with 1–10 employees. The company is currently in the Pre-Funding stage, focusing on developing its biopharmaceutical solutions.
Business overview
Life Matters is a preclinical-stage biopharmaceutical company dedicated to combating antibiotic-resistant bacteria. The company's core technology involves preventing bacterial biofilm growth, a critical mechanism for bacterial survival against antibacterial agents and the host's immune system. Its lead product, IBF-2, is an API compound with an innovative mechanism of action designed to attenuate biofilm formation, thereby making infections more treatable. Life Matters primarily serves the healthcare and life sciences industries, specifically targeting pharmaceuticals and healthcare providers with solutions for chronic lung infections and other conditions where biofilm-related P. aeruginosa contributes to morbidity and mortality.
Log in to access full profile ›Company Intelligence Q&A
- What is Life Matters' primary focus?
- Life Matters is a preclinical-stage biopharmaceutical company focused on tackling antibiotic-resistant bacteria by preventing biofilm formation.
- When was Life Matters founded?
- Life Matters was founded in July 2016.
- Who are the co-founders of Life Matters?
- Life Matters was co-founded by Amit Elbaz, Prof. Robert S. Marks, Karina Golberg, and Prof. Ariel Kushmaro.
- What is the lead product developed by Life Matters?
- Life Matters' lead product is API, IBF-2, a compound with an innovative mechanism of action that attenuates the biofilm mode of growth.
- What problem does Life Matters aim to solve?
- Life Matters aims to solve the problem of antibiotic-resistant bacteria, particularly those acquired in hospitals, by preventing their biofilm mode of growth to make infections more treatable.